<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01170923</url>
  </required_header>
  <id_info>
    <org_study_id>AMC 08-351</org_study_id>
    <nct_id>NCT01170923</nct_id>
  </id_info>
  <brief_title>FDG-PET Scan Response Guided Chemotherapy Strategy for Advanced Non-small Cell Lung Cancer</brief_title>
  <official_title>Standard Chemotherapy Strategy Versus Changing Chemotherapy Strategy as to FDG-PET Response After 1st Cycle of Standard Chemotherapy for Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The usual response to chemotherapy is decided through the image change by computed tomography&#xD;
      (CT), which is taken at least 6-9 weeks.&#xD;
&#xD;
      In order to predict the response to chemotherapy earlier, patients received FDG-PET scan at&#xD;
      the first cycle of chemotherapy. Chemotherapy was guided by the metabolic response by FDG-PET&#xD;
      scan.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, Open-label, Randomized phase II, single institution trial that compared&#xD;
      chemotherapy guided by traditional evaluation based on RECIST versus chemotherapy guided by&#xD;
      FDG-PET (metabolic) response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <primary_completion_date type="Anticipated">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in response rate</measure>
    <time_frame>within 4 cycles</time_frame>
    <description>The usual response rate of GenexolPM/Cisplatin chemotherapy is 30-40%. This trial will assess whether the changing chemotherapy strategy using FDG-PET can increase response rate by 15%.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>FDG-PET guided</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy regimen will be changed depending on metabolic response.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT guided</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemotherapy regimen will be changed depending on CT findings (RECIST).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FDR-PET</intervention_name>
    <description>FDR-PET performed after 1 cycle of chemotherapy</description>
    <arm_group_label>FDG-PET guided</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CT</intervention_name>
    <description>CT performed after 3 cycles of chemotherapy</description>
    <arm_group_label>CT guided</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed non-small cell carcinoma.&#xD;
&#xD;
          2. Stage IIIB (wet) or IV advanced NSCLC.&#xD;
&#xD;
          3. No evidence of prior malignancies for 3 years except treated basal cell or squamous&#xD;
             cell carcinoma of skin and carcinoma in situ of uterine cervix.&#xD;
&#xD;
          4. Measurable disease by RECIST criteria.&#xD;
&#xD;
          5. Adequate organ function as follows.&#xD;
&#xD;
               -  Seum AST/ALT &lt; 2.5 x Upper normal limit (UNL) (if hepatic metastasis &lt; 5 x UNL)&#xD;
&#xD;
               -  Total bilirubin &lt; 1.5 x UNL&#xD;
&#xD;
               -  Serum creatinine &lt; 1.5 mg/dL&#xD;
&#xD;
               -  Absolute neutrophil count &gt; 1500/uL&#xD;
&#xD;
               -  Platelet &gt; 100,000/uL&#xD;
&#xD;
               -  Hemoglobin &gt; 9.0 g/dL&#xD;
&#xD;
          6. ECOG Performance status 0-1 7 Age &gt; 18&#xD;
&#xD;
        8. If previously treated with major surgery, it should be over at least 4 weeks. And if&#xD;
        previously treated with radiotherapy, it should be over at least 2 weeks.&#xD;
&#xD;
        9. Written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous chemotherapy.&#xD;
&#xD;
          2. Symptomatic brain metastasis.&#xD;
&#xD;
          3. Concurrent severe medical illness.&#xD;
&#xD;
          4. Pregnancy and lactation.&#xD;
&#xD;
          5. If there are findings which may increase risk with chemotherapy or inhibit to analyze&#xD;
             the result of clinical trial.&#xD;
&#xD;
               -  Uncontrolled diabetes mellitus.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang-We Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>July 27, 2010</study_first_submitted>
  <study_first_submitted_qc>July 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2010</study_first_posted>
  <last_update_submitted>July 27, 2010</last_update_submitted>
  <last_update_submitted_qc>July 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sang-We Kim</name_title>
    <organization>Asan Medical Center</organization>
  </responsible_party>
  <keyword>non small cell lung cancer</keyword>
  <keyword>FDG PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

